Human/Mouse CXCL12/SDF-1 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB310
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Lys22-Lys89
Accession # Q6ICW0
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human/Mouse CXCL12/SDF-1 Antibody
Chemotaxis Induced by CXCL12/SDF‑1 alpha and Neutral-ization by Human/Mouse CXCL12/SDF‑1 Antibody.
Recombinant Human/Feline/ Rhesus Macaque CXCL12/ SDF-1a (Catalog # 350-NS) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR4 in a dose-dependent manner (orange line). Chemotaxis elicited by Recombinant Human/Feline/ Rhesus Macaque CXCL12/ SDF-1a (2 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Mouse CXCL12/SDF-1 Monoclonal Antibody (Catalog # MAB310). At 111 µg/mL, this antibody will neutralize > 50% of the chemotactic effect.Detection of Mouse CXCL12/SDF-1 by In vivo assay
Enumeration of bone marrow and blood Lin−/Sca1+ cell numbers following stroke and SDF1-A Antibody.(A) Twenty-four hour post stroke+SDF1-A antibody mice show a marked increase in the number of Lin−/Sca1+ cells present in the bone marrow compared to controls. (B) Twenty-four hour post stroke mice showed a marked decrease in the mobilization of these cells to the blood. * P<0.05. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24465621), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse CXCL12/SDF-1 by In vivo assay
Administration of Lin−/Sca1+ cells post stroke.A. Administration of Lin−/Sca1+ cells post stroke significantly reduced infarct volume at 24 hours post stroke (*P<0.05). B. Administration of the Lin−/Sca1+ cells with an SDF1-A antibody (AB) no longer demonstrates a beneficial reduction in the infarct volume (p = NS). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24465621), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human/Mouse CXCL12/SDF-1 Antibody
Neutralization
Measured by its ability to neutralize CXCL12/SDF‑1 alpha-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR4. At 111 μg/mL, this antibody will neutralize > 50% of the chemotactic effect due to 2 ng/mL Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF‑1 alpha.
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CXCL12/SDF-1
CXCL12, also known as SDF-1 (stromal cell-derived factor 1) and PBSF (Pre-B cell growth stimulatory factor), is a member of the CXC chemokine superfamily. Two alternatively spliced mRNAs encode CXCL12 alpha (89 aa residues) and CXCL12 beta (93 aa residues) that differ by the addition of 4 amino acids at the carboxy-terminus. Human and mouse CXCL12 are highly conserved. Mature human and mouse CXCL12 differ only by 1 amino acid.
Alternate Names
Gene Symbol
UniProt
Additional CXCL12/SDF-1 Products
Product Documents for Human/Mouse CXCL12/SDF-1 Antibody
Product Specific Notices for Human/Mouse CXCL12/SDF-1 Antibody
For research use only